P060 Rituximab as third line therapy in IgG4-Related Disease: experience from a multi-centre cohort

Introduction

Immunoglobulin G4-Related Disease (IgG4RD) is a rare multi-organ fibro-inflammatory immune-mediated disorder that has a predilection for the pancreas and bile ducts, leading to organ damage and failure, and an increased risk of malignancy. B cells play a crucial role in disease pathogenesis and disease relapse. Rituximab (anti-CD20 chimeric monoclonal antibody) has received UK NICE approval for third-line therapy for...